FF/UMEC/VI
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
FF/UMEC/VI (fluticasone/umeclidinium/vilanterol; GlaxoSmithKline) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (umeclidinium), a long-acting beta 2 agonist (vilanterol), and an inhaled corticosteroid (fluticasone). FF/UMEC/VI is in Phase III development for the treatment of moderate to very severe chronic obstructive pulmonary disease.
Analyst Outlook
Due to its potential first-to-market status in the US, FF/UMEC/VI (fluticasone/umeclidinium/vilanterol; GlaxoSmithKline) is forecast to see the greatest uptake among the late-phase triple combination therapies being developed for the treatment of chronic obstructive pulmonary disease (COPD). While pulmonologists and primary care physicians are excited about the prospect of triple therapies simplifying the management of COPD for patients with advanced disease, payers in the US and EU hold a more reserved outlook as they are unconvinced about the long-term efficacy of such therapies. In addition, payers are concerned about the potential overuse of more costly triple therapies, particularly in light of the availability of a series of cost-effective therapies, such as the long-acting beta 2 agonist/long-acting muscarinic antagonists (LABA/LAMAs). As such, Datamonitor Healthcare forecasts FF/UMEC/VI’s prescribing to be limited to very severe patients who are currently using multiple inhalers.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 FF/UMEC/VI : Chronic obstructive pulmonary disease
LIST OF FIGURES
8 Figure 1: FF/UMEC/VI for COPD – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of FF/UMEC/VI for COPD
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of FF/UMEC/VI for COPD
LIST OF TABLES
4 Table 1: FF/UMEC/VI drug profile
6 Table 2: Phase III clinical trials for FF/UMEC/VI in COPD
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Ultibro 
Sign up to the